サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1363172

泌尿生殖器治療薬の市場規模、シェア、動向分析レポート：適応症別、製品別、地域別、セグメント予測、2023年～2030年

Genitourinary Drugs Market Size, Share & Trends Analysis Report By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, UTI & STD), By Product (Hormonal Therapy, Gynecological), By Region, And Segment Forecasts, 2023 - 2030
出版日: | 発行: Grand View Research | ページ情報: 英文 110 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
泌尿生殖器治療薬の市場規模、シェア、動向分析レポート：適応症別、製品別、地域別、セグメント予測、2023年～2030年
出版日: 2023年09月22日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

泌尿生殖器治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、泌尿生殖器治療薬の世界市場規模は2023年から2030年にかけてCAGR 1.1%で拡大し、2030年には317億5,000万米ドルに達する見込みです。

この分野は、主な企業による高額の研究開発投資が原動力となり、新薬候補の大規模な開発につながると期待されています。このため、泌尿生殖器系疾患に対する効率的な治療選択肢を提供する泌尿生殖器系医薬品市場への薬剤の流入が急ピッチで増加すると推測されます。

加えて、医薬品回収の増加も、標的治療メカニズムを持つ比較的新しい先進的な医薬品の開発に対する高い臨床的緊急性を煽っています。これらの要因を総合すると、予測期間中、この業界には大きな成長機会がもたらされることになります。

さらに、大手市場プレイヤーの世界的プレゼンスが高まることで、泌尿生殖器疾患の治療選択肢に関する患者や医師の意識レベルが高まると予想されます。これにより、予測期間中の泌尿生殖器市場の成長可能性はさらに拡大すると予想されます。ジェネリック医薬品競争の激化、偽造医薬品の増加、いくつかの特許失効が控えていることから、市場成長は今後数年間で鈍化すると予想されます。

泌尿生殖器治療薬市場レポートハイライト

  • 前立腺がんは、世界の罹患率の上昇により、2022年には適応症セグメントで最大のシェアを占めました。また、プロテオミクス技術の進歩やスクリーニング・診断方法の改善が、圧倒的なシェアの背景にあると推定されます。
  • 2022年には、北米が37.0％以上のシェアで世界の泌尿生殖器治療薬市場を独占しました。この圧倒的なシェアは、同地域の疾病負担の大きさに起因しており、そのため研究者やヘルスケア専門家の高度な製剤技術への傾倒を促し、同分野の成長範囲を拡大すると予想されます。
  • アジア太平洋地域のCAGRは予測期間中に4.8%を超えると予想されています。この急激な成長率は、医療支出の増加、主要な業界別プレイヤーの取り組みによる臨床研究および製造施設のインフラ品質の向上に起因しています。
  • 市場参入企業は、新製品開拓や共同戦略によって市場シェアを拡大し、この分野での存在感を高めています。例えば、ノバルティスAGは2023年3月、Aduro Biotech社との提携を通じてがん免疫療法の研究イニシアチブをさらに強化し、次世代がん免疫療法の発見と開発に向けた活動を強化しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 泌尿生殖器治療薬市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 普及と成長の見通しマッピング
  • 市場力学
    • 市場促進要因の分析
    • 市場抑制要因分析
  • 泌尿生殖器治療薬市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 泌尿生殖器治療薬市場：適応症別推定・動向分析

  • 泌尿生殖器治療薬市場：重要なポイント
  • 泌尿生殖器治療薬市場：動向と市場シェア分析、2022年および2030年
  • 前立腺がん
  • 卵巣がん
  • 膀胱がん
  • 子宮頸がん
  • 腎がん
  • 勃起不全
  • 尿路感染症
  • 尿失禁と過活動膀胱
  • 性感染症
  • 間質性膀胱炎
  • 血尿
  • 前立腺肥大症

第5章 泌尿生殖器治療薬市場：製品別推定・動向分析

  • 泌尿生殖器治療薬市場：重要なポイント
  • 泌尿生殖器治療薬市場：動向と市場シェア分析、2022年および2030年
  • 泌尿器科
  • ホルモン療法
  • 婦人科
  • 抗感染症薬
  • その他

第6章 泌尿生殖器治療薬市場：地域別推定・動向分析

  • 地域別の展望
  • 地域別の泌尿生殖器治療薬市場：重要なポイント
  • 北米
    • 市場推計・予測、2018～2030年
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • スウェーデン
    • ノルウェー
    • デンマーク
  • アジア太平洋地域
    • 日本
    • 中国
    • インド
    • オーストラリア
    • タイ
    • 韓国
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • アルゼンチン
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 市場参入企業の分類
    • Abbott
    • Bristol-Myers Squibb Co.
    • Novartis AG
    • Genentech, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Ionis Pharmaceuticals, Inc.
    • Eli Lilly and Company
    • Merck & Co. Inc.
    • Pfizer, Inc.
    • AstraZeneca
    • GlaxoSmithKline
    • Teva Pharmaceutical Industries Ltd.
    • Bayer AG
    • Allergan.
    • Antares Pharma
図表

List of Tables

  • Table 1 List of abbreviations
  • Table 2 North America genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 3 North America genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 4 North America genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 5 U.S. genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 6 U.S. genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 7 Canada genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 8 Canada genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 9 Europe genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 10 Europe genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 11 Europe genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 12 Germany genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 13 Germany genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 14 UK genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 15 UK genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 16 France genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 17 France genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 18 Italy genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 19 Italy genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 20 Spain genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 21 Spain genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 22 Sweden genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 23 Sweden genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 24 Norway genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 25 Norway genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 26 Denmark genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 27 Denmark genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 28 Asia Pacific genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 31 China genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 32 China genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 33 Japan genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 34 Japan genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 35 India genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 36 India genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 37 Australia genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 38 Australia genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 39 Thailand genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 40 Thailand genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 41 South Korea genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 42 South Korea genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 43 Latin America genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 44 Latin America genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 45 Latin America genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 46 Brazil genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 47 Brazil genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 48 Mexico genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 49 Mexico genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 50 Argentina genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 51 Argentina genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 52 Middle East and Africa genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 53 Middle East and Africa genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 54 Middle East and Africa genitourinary drugs market, by region, 2018 - 2030 (USD Million)
  • Table 55 South Africa genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 56 South Africa genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 57 Saudi Arabia genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 58 Saudi Arabia genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 59 UAE genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 60 UAE genitourinary drugs market, by product, 2018 - 2030 (USD Million)
  • Table 61 Kuwait genitourinary drugs market, by indication, 2018 - 2030 (USD Million)
  • Table 62 Kuwait genitourinary drugs market, by product, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Genitourinary drugs: market outlook
  • Fig. 9 Genitourinary Drugs Competitive Insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Genitourinary drugs market driver impact
  • Fig. 15 Genitourinary drugs market restraint impact
  • Fig. 16 Genitourinary drugs market strategic initiatives analysis
  • Fig. 17 Genitourinary drugs market: Indication movement analysis
  • Fig. 18 Genitourinary drugs market: Indication outlook and key takeaways
  • Fig. 19 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Ovarian cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Bladder cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 Cervical cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 23 Renal cancer market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 24 Erectile dysfunction market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 Urinary tract infections market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Urinary incontinence & overactive bladder market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 27 Sexually transmitted diseases market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 28 Interstitial cystitis market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 29 Hematuria market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 30 Benign prostatic hyperplasia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 31 Genitourinary drugs market: Product movement analysis
  • Fig. 32 Genitourinary drugs market: Product outlook and key takeaways
  • Fig. 33 Urologicals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Hormonal therapy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 35 Gynecological market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Anti-infectives market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Global genitourinary drugs market: Regional movement analysis
  • Fig. 39 Global genitourinary drugs market: Regional outlook and key takeaways
  • Fig. 40 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 42 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 57 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 59 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
目次
Product Code: GVR-1-68038-285-3

Genitourinary Drugs Market Growth & Trends:

The global genitourinary drugs market size is expected to reach USD 31.75 billion by 2030, expanding at a CAGR of 1.1% from 2023 to 2030, according to a new report by Grand View Research, Inc.. This sector is expected to be driven by high R&D investments undertaken by the key companies, which is expected to result in the large-scale development of new drug candidates. This is presumed to increase the influx of drugs at a rapid pace into the genitourinary drugs market hence providing efficient treatment alternatives for numerous genitourinary disorders.

In addition, growing incidence of drug recalls is fueling the high clinical urgency to develop relatively new and advanced drugs with targeted therapy mechanisms. These factors cumulatively are slated to present the vertical with considerable growth opportunities over the forecast period.

Furthermore, increasing global presence of the major market players is anticipated to raise the awareness levels pertaining to treatment alternatives for genitourinary diseases amongst the patients as well as the physicians. This is further expected to widen the genitourinary market growth potential during the forecast period. Growing generic drugs competition, rising presence of counterfeit drugs, and with several patent expirations in the horizon, the market growth is expected to slow down over the coming years.

Genitourinary Drugs Market Report Highlights:

  • Prostate cancer held the largest share of the indication segment in 2022 owing to the rising global incidence of the condition. In addition, advances in proteomics technology and improved screening and diagnostic procedures are presumed to be responsible for the dominant share.
  • In 2022, North America dominated the global genitourinary drugs vertical with a share of over 37.0%. The dominant share is attributable to the high disease burden present in this region, thus driving the inclination of researchers and healthcare professionals toward advanced formulation technologies, which is anticipated to widen the growth scope for this sector
  • Asia Pacific is expected to witness a lucrative CAGR of over 4.8% during the forecast period. The exponential growth rate can be attributed to the rising healthcare spending and the improving infrastructure quality of clinical research and manufacturing facilities owing to the initiatives of the key vertical players
  • The prominent participants are employing new product development and collaborative strategies to capture greater market share and increase their presence in this sector. For instance, in March 2023, Novartis AG further enhanced its cancer immunotherapy research initiative through collaboration with Aduro Biotech to increase its activities toward discovery and development in next generation cancer immunotherapy

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Indication
    • 1.1.2. Product
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Indication outlook
    • 2.2.2. Product outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Genitourinary Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Genitourinary Drugs Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Genitourinary Drugs Market: Indication Estimates & Trend Analysis

  • 4.1. Genitourinary Drugs Market: Key Takeaways
  • 4.2. Genitourinary Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Prostate Cancer
    • 4.3.1. Prostate cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. Ovarian Cancer
    • 4.4.1. Ovarian cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Bladder Cancer
    • 4.5.1. Bladder cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Cervical Cancer
    • 4.6.1. Cervical cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.7. Renal Cancer
    • 4.7.1. Renal cancer market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.8. Erectile Dysfunction
    • 4.8.1. Erectile dysfunction market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.9. Urinary Tract Infections
    • 4.9.1. Urinary tract infections market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.10. Urinary Incontinence & Overactive Bladder
    • 4.10.1. Urinary incontinence & overactive bladder market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.11. Sexually Transmitted Diseases
    • 4.11.1. Sexually transmitted diseases market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.12. Interstitial Cystitis
    • 4.12.1. Interstitial cystitis market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.13. Hematuria
    • 4.13.1. Hematuria market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.14. Benign Prostatic Hyperplasia
    • 4.14.1. Benign prostatic hyperplasia market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Genitourinary Drugs Market: Product Estimates & Trend Analysis

  • 5.1. Genitourinary Drugs Market: Key Takeaways
  • 5.2. Genitourinary Drugs Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Urologicals
    • 5.3.1. Urologicals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. Hormonal Therapy
    • 5.4.1. Hormonal therapy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Gynecological
    • 5.5.1. Gynecological market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Anti-infectives
    • 5.6.1. Anti-infectives market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Genitourinary Drugs Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Outlook
  • 6.2. Genitourinary Drugs Market by Region: Key Takeaway
  • 6.3. North America
    • 6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.4. Europe
    • 6.4.1. UK
      • 6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.2. Germany
      • 6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.3. France
      • 6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.4. Italy
      • 6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.5. Spain
      • 6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.6. Sweden
      • 6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.7. Norway
      • 6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.4.8. Denmark
      • 6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Japan
      • 6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.2. China
      • 6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.3. India
      • 6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.4. Australia
      • 6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.5. Thailand
      • 6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.6. Latin America
    • 6.6.1. Brazil
      • 6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.2. Mexico
      • 6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
  • 6.7. MEA
    • 6.7.1. Saudi Arabia
      • 6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.3. UAE
      • 6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
    • 6.7.4. Kuwait
      • 6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Market Participant Categorization
    • 7.2.1. Abbott
      • 7.2.1.1. Company overview
      • 7.2.1.2. Financial performance
      • 7.2.1.3. Product benchmarking
      • 7.2.1.4. Strategic initiatives
    • 7.2.2. Bristol-Myers Squibb Co.
      • 7.2.2.1. Company overview
      • 7.2.2.2. Financial performance
      • 7.2.2.3. Product benchmarking
      • 7.2.2.4. Strategic initiatives
    • 7.2.3. Novartis AG
      • 7.2.3.1. Company overview
      • 7.2.3.2. Financial performance
      • 7.2.3.3. Product benchmarking
      • 7.2.3.4. Strategic initiatives
    • 7.2.4. Genentech, Inc.
      • 7.2.4.1. Company overview
      • 7.2.4.2. Financial performance
      • 7.2.4.3. Product benchmarking
      • 7.2.4.4. Strategic initiatives
    • 7.2.5. F. Hoffmann-La Roche Ltd.
      • 7.2.5.1. Company overview
      • 7.2.5.2. Financial performance
      • 7.2.5.3. Product benchmarking
      • 7.2.5.4. Strategic initiatives
    • 7.2.6. Ionis Pharmaceuticals, Inc.
      • 7.2.6.1. Company overview
      • 7.2.6.2. Financial performance
      • 7.2.6.3. Product benchmarking
      • 7.2.6.4. Strategic initiatives
    • 7.2.7. Eli Lilly and Company
      • 7.2.7.1. Company overview
      • 7.2.7.2. Financial performance
      • 7.2.7.3. Product benchmarking
      • 7.2.7.4. Strategic initiatives
    • 7.2.8. Merck & Co. Inc.
      • 7.2.8.1. Company overview
      • 7.2.8.2. Financial performance
      • 7.2.8.3. Product benchmarking
      • 7.2.8.4. Strategic initiatives
    • 7.2.9. Pfizer, Inc.
      • 7.2.9.1. Company overview
      • 7.2.9.2. Financial performance
      • 7.2.9.3. Product benchmarking
      • 7.2.9.4. Strategic initiatives
    • 7.2.10. AstraZeneca
      • 7.2.10.1. Company overview
      • 7.2.10.2. Financial performance
      • 7.2.10.3. Product benchmarking
      • 7.2.10.4. Strategic initiatives
    • 7.2.11. GlaxoSmithKline
      • 7.2.11.1. Company overview
      • 7.2.11.2. Financial performance
      • 7.2.11.3. Product benchmarking
      • 7.2.11.4. Strategic initiatives
    • 7.2.12. Teva Pharmaceutical Industries Ltd.
      • 7.2.12.1. Company overview
      • 7.2.12.2. Financial performance
      • 7.2.12.3. Product benchmarking
      • 7.2.12.4. Strategic initiatives
    • 7.2.13. Bayer AG
      • 7.2.13.1. Company overview
      • 7.2.13.2. Financial performance
      • 7.2.13.3. Product benchmarking
      • 7.2.13.4. Strategic initiatives
    • 7.2.14. Allergan.
      • 7.2.14.1. Company overview
      • 7.2.14.2. Financial performance
      • 7.2.14.3. Product benchmarking
      • 7.2.14.4. Strategic initiatives
    • 7.2.15. Antares Pharma
      • 7.2.15.1. Company Overview
      • 7.2.15.2. Financial performance
      • 7.2.15.3. Product benchmarking
      • 7.2.15.4. Strategic initiatives